IPO

Horizon Robotics Formally Files Hong Kong IPO Application, aiming to enhance people's safety and experience in passenger vehicles

Retrieved on: 
Tuesday, March 26, 2024
BYD, Growth, Original equipment manufacturer, Knowledge, Research, ADAS, Sale, Robotics, Software, Motherboard, IPO, Geely, City, OEM, Safety, CIC, SAIC, Video game

Smart vehicles with autonomous features can free up time and boost productivity for drivers and passengers during these long commutes.

Key Points: 
  • Smart vehicles with autonomous features can free up time and boost productivity for drivers and passengers during these long commutes.
  • Faced with a broad market prospect, there are also more and more players participating in the smart vehicle industry.
  • Recently, Horizon Robotics, a leading provider of ADAS and AD solutions for passenger vehicles, submitted its IPO application to the Hong Kong Stock Exchange and plans to list on the Main Board.
  • From an industry perspective, China is the world's largest smart vehicles market, with sales volume of smart vehicles of 12.4 million in 2023.

W Capital Markets Partners with VCI Global to Offer Comprehensive Capital Markets Strategy Services to List Clients on the NASDAQ

Retrieved on: 
Monday, March 25, 2024
Organization, Dato, Sale, IPO, Robotics, Financial services

Ltd. ("W Capital") has entered into a collaboration agreement with VCI Global Limited (NASDAQ: VCIG) ("VCI Global"), for the purpose of introducing prospective clients to one another.

Key Points: 
  • Ltd. ("W Capital") has entered into a collaboration agreement with VCI Global Limited (NASDAQ: VCIG) ("VCI Global"), for the purpose of introducing prospective clients to one another.
  • VCI Global is a diversified holding company which primarily offers consulting services in capital markets, real estate, AI, and technology.
  • Under this collaboration agreement, VCI Global will introduce clients, to W Capital, who may have an interest in the investment banking services offered by W Capital and will collaborate with W Capital to jointly advise clients with interest in seeking initial public offering listings on the stock exchanges in the United States, particularly the Nasdaq Capital Markets.
  • Of course, we are pleased to be able to reciprocate W Capital' actions by passing clients to them with interest in investment banking services," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

Muangthai Capital Elevates to World Class Status as Premier Thai Microfinance Institution

Retrieved on: 
Wednesday, March 13, 2024
Momentum, Electricity, DEG, THB, Risk management, Growth, MTC, Fintech, Risk, SMBC, MSCI, Ministry of Finance, Bank, Internet, JICA, Interview, IPO, Computer, Mouth, Paper

BANGKOK, Mar 13, 2024 - (ACN Newswire) - Mr. Parithad Petampai, Deputy Managing Director of Muangthai Capital, a leading player in the microfinance sector, recently shared his visionary insights on propelling the company towards global recognition as a world class Thai microfinance institution.

Key Points: 
  • BANGKOK, Mar 13, 2024 - (ACN Newswire) - Mr. Parithad Petampai, Deputy Managing Director of Muangthai Capital, a leading player in the microfinance sector, recently shared his visionary insights on propelling the company towards global recognition as a world class Thai microfinance institution.
  • The key changes lie in refining processes and structures to foster growth and profitability over immediate gains.
  • Our vision is for Muangthai Capital to be a World Class Microfinance Company.
  • We will continue to focus on core services, being customer and employee centric, with a sustainable focus for Muangthai Capital to be a World Class Thai Microfinance Company.

Jianzhi Education Technology Group Company Limited Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, April 9, 2024
Research, Administration, Development, Growth, Partnership, Travel, Software, IPO, American depositary receipt, ADS, Marketing, Cryptocurrency

The Company’s gross profit margin improved to 3.7% for the year ended December 31, 2023 from negative 1.1% for the year ended December 31, 2022.

Key Points: 
  • The Company’s gross profit margin improved to 3.7% for the year ended December 31, 2023 from negative 1.1% for the year ended December 31, 2022.
  • Sales and Marketing Expenses: The sales and marketing expenses was RMB7.6 million (US$1.1 million) and RMB7.1 million for the fiscal years 2023 and 2022, respectively.
  • General and Administrative Expenses: The general and administrative expenses decreased to RMB22.2 million (US$3.1 million) for the fiscal year 2023 from RMB53.2 million for the fiscal year 2022.
  • Accordingly, the Company charged impairment of RMB155.3 million (US$21.9 million) against long-term prepayments for the year ended December 31, 2023.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Form, Patient, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Rett syndrome, Prospectus, Complaint, P.C, Clinical trial, MCI, Radar, File, Register, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

SNOW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Snowflake Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 9, 2024
Scarpelli, Snowflake Inc., IPO, SNOW, Complaint, Court, Person

Snowflake is a data cloud platform that enables customers to consolidate data into a single source, build data-driven applications, and share data.

Key Points: 
  • Snowflake is a data cloud platform that enables customers to consolidate data into a single source, build data-driven applications, and share data.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Snowflake you have until April 29, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against AXT, Inc. (AXTI)

Retrieved on: 
Monday, April 8, 2024
Research, AXT, IPO, News, IP, Private investigator

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI ).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI ).
  • The investigation concerns whether AXT and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX

Retrieved on: 
Monday, April 8, 2024
Titan, Psoriasis, Class, IPO, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.